Compare HIVE & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIVE | SLDB |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2017 |
| Metric | HIVE | SLDB |
|---|---|---|
| Price | $2.96 | $9.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $6.44 | ★ $16.36 |
| AVG Volume (30 Days) | ★ 23.0M | 877.9K |
| Earning Date | 02-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $297,791,000.00 | $8,094,000.00 |
| Revenue This Year | $169.51 | N/A |
| Revenue Next Year | $39.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 158.32 | N/A |
| 52 Week Low | $1.73 | $3.79 |
| 52 Week High | $7.84 | $11.45 |
| Indicator | HIVE | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 51.29 |
| Support Level | $2.63 | $6.25 |
| Resistance Level | $3.40 | $11.45 |
| Average True Range (ATR) | 0.23 | 0.43 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 53.90 | 43.67 |
HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.